Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Florencia Mauro"'
Autor:
Sofia Bruni, Florencia Mauro, Cecilia Proietti, Rosalia Cordo-Russo, Mercogliano María Florencia, Roxana Schillaci
Publikováno v:
Cancer Research. 83:P1-11
Background. Clinical trials have demonstrated that trastuzumab deruxtecan (T-DXd) provides a durable responses for patients with HER2-positive and HER2 low metastatic breast cancer (BC). With T-DXd treatment, approximately 50% of patients with HER2+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d406db271a1d28decf1944d2f2430002
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-12
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-12
Autor:
Roxana Schillaci, Sofia Bruni, Florencia Mauro, María F Mercogliano, Agustina Roldan-Deamicis, Cecilia J Proietti, Rosalía Cordo-Russo, Gloria Inurrigarro, Agustina Dupont, Carla Adami, Daniel Lopez Della Vecchia, Sabrina Barchuck, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G Gercovich, Patricia V Elizalde
Publikováno v:
Cancer Research. 82:P5-13
Background HER2-positive (+) and triple negative breast cancer (TNBC) have the worst survival among BC. BC patients are treated with chemotherapy (CT) and/or radiotherapy (RT), and HER2+ BC patients also receive targeted therapies, such as trastuzuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ea5a7e8d26549966ddc698723e940da
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-32
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-32
Autor:
Sofia Bruni, Mara De Martino, Florencia Mauro, Maria Mercogliano, Cecilia Proietti, Rosalia Cordo-Russo, Patricia Elizalde, Roxana Schillaci
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64112cffa49789a21d47bf65439b18a9
https://doi.org/10.1136/jitc-2022-sitc2022.0877
https://doi.org/10.1136/jitc-2022-sitc2022.0877
Autor:
Patricia Elizalde, Martina Belmonte, Mauro Cenciarini, Agustina Roldan Deamicis, Santiago Madera, Florencia Mercogliano, Florencia Mauro, Sofia Bruni, Rosalía Cordo Russo, Roxana Schillaci, Cecilia Proietti
Publikováno v:
Journal of the Endocrine Society. 6:A719-A719
Enhancer of Zeste homolog 2 (EZH2) is a histone methyltransferase which catalyzes the trimethylation of lysine 27 of histone H3 (H3K27me3), an epigenetic mark associated with chromatin compaction and transcriptional repression of target genes. This c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2bc5d35f8cc95dc0f93f1429a510bf9
https://doi.org/10.1210/jendso/bvac150.1481
https://doi.org/10.1210/jendso/bvac150.1481